{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T02:21:10Z","timestamp":1780626070321,"version":"3.54.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T00:00:00Z","timestamp":1649116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>In newly diagnosed neurocysticercosis (NCC) with seizures, the choice of anti-seizure medication (ASM) seems to be arbitrary due to a lack of comparative studies. Although oxcarbazepine (OXC) is often considered efficacious for focal seizures in NCC, due to adverse effects, newer ASMs like levetiracetam (LCM) and lacosamide are also being explored.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study was performed by case record review of children with newly diagnosed solitary viable parenchymal NCC aged 4\u201318years who received lacosamide and OXC at least for 12 weeks between August 2019 and April 2021, from a prospective registry of a tertiary care teaching hospital in north India. Seizure control, electroencephalographic abnormalities, resolution of inflammatory granulomas and adverse effects were compared between two arms at 12 and 24 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Total 31 (8.3\u2009\u00b1\u20094.7\u2009years, 19 boys) and 72 (8.6\u2009\u00b1\u20094.2\u2009years, 43 boys) completed at least 12\u2009weeks follow-up in LCM and OXC groups, out of which 2 and 51 completed at least 24\u2009weeks follow-up in LCM and OXC groups, respectively. The occurrence of breakthrough seizure was comparable in both arms at 12 and 24\u2009weeks (1\/31 and 2\/22 in lacosamide group vs. 2\/72 and 4\/51 in OXC group, p\u2009=\u20090.66 and 0.59, respectively). Patients receiving OXC had more frequent treatment-emergent adverse events (p\u2009=\u20090.0001) and four patients required discontinuation due to severe adverse events (SAEs), while none in the lacosamide group had SAEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Lacosamide appears to be efficacious and safe for achieving seizure freedom in patients with solitary viable parenchymal neurocysticercosis.<\/jats:p><\/jats:sec>","DOI":"10.1093\/tropej\/fmac032","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T11:10:52Z","timestamp":1650021052000},"source":"Crossref","is-referenced-by-count":12,"title":["Comparative Efficacy and Safety of Lacosamide and Oxcarbazepine for Seizure Control in Children with Newly Diagnosed Solitary Neurocysticercosis"],"prefix":"10.1093","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7003-7218","authenticated-orcid":false,"given":"Indar Kumar","family":"Sharawat","sequence":"first","affiliation":[{"name":"Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7831-9271","authenticated-orcid":false,"given":"Prateek Kumar","family":"Panda","sequence":"additional","affiliation":[{"name":"Pediatric Neurology Division, Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-2399","authenticated-orcid":false,"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Sherwani","sequence":"additional","affiliation":[{"name":"Department of Radiodiagnosis and Imaging, All India Institute of Medical Sciences, Rishikesh 249203, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,4,23]]},"reference":[{"key":"2022042312263975000_fmac032-B1","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1007\/s13312-021-2311-6","article-title":"Management of neurocysticercosis in children: association of Child Neurology Consensus Guidelines","volume":"58","author":"Sankhyan","year":"2021","journal-title":"Indian Pediatr"},{"key":"2022042312263975000_fmac032-B2","doi-asserted-by":"crossref","first-page":"812","DOI":"10.4269\/ajtmh.19-0278","article-title":"An ambispective cohort study to assess seizure recurrences in children with calcified parenchymal neurocysticercosis","volume":"101","author":"Modak","year":"2019","journal-title":"Am J Trop Med Hyg"},{"key":"2022042312263975000_fmac032-B3","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jiph.2018.02.006","article-title":"Recurrent encephalopathy in milliary neurocysticercosis: an uncommon manifestation of a common infection","volume":"11","author":"Sharawat","year":"2018","journal-title":"J Infect Public Health"},{"key":"2022042312263975000_fmac032-B4","doi-asserted-by":"crossref","first-page":"945","DOI":"10.4269\/ajtmh.18-88751","article-title":"Diagnosis and treatment of neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)","volume":"98","author":"White","year":"2018","journal-title":"Am J Trop Med Hyg"},{"key":"2022042312263975000_fmac032-B5","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(07)60460-7","article-title":"The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial","volume":"369","author":"Marson","year":"2007","journal-title":"Lancet"},{"key":"2022042312263975000_fmac032-B6","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1002\/phar.1855","article-title":"Efficacy and tolerability of antiepileptic drugs in patients with focal epilepsy: systematic review and network meta-analyses","volume":"36","author":"Campos","year":"2016","journal-title":"Pharmacotherapy"},{"key":"2022042312263975000_fmac032-B7","first-page":"414","article-title":"[Adverse effects of oxcarbazepine]","volume":"17","author":"Fang","year":"2015","journal-title":"Zhongguo Dang Dai Er Ke Za Zhi"},{"key":"2022042312263975000_fmac032-B8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/ane.13355","article-title":"Carbamazepine versus levetiracetam in epilepsy due to neurocysticercosis","volume":"143","author":"Santhosh","year":"2021","journal-title":"Acta Neurol Scand"},{"key":"2022042312263975000_fmac032-B9","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1474-4422(16)30292-7","article-title":"Efficacy, safety, and tolerability of lacosamide monotherapy versus controlled-release carbamazepine in patients with newly diagnosed epilepsy: a phase 3, randomised, double-blind, non-inferiority trial","volume":"16","author":"Baulac","year":"2017","journal-title":"Lancet Neurol"},{"key":"2022042312263975000_fmac032-B10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1684\/epd.2019.1069","article-title":"Abdominal epilepsia partialis continua in neurocysticercosis","volume":"21","author":"Asranna","year":"2019","journal-title":"Epileptic Disord"},{"key":"2022042312263975000_fmac032-B11","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1212\/WNL.94.15_supplement.2738","article-title":"New onset sensorimotor epilepisa partialis continua as an initial presentation of neurocysticercosis (2738)","volume":"94","author":"Thomason","year":"2020","journal-title":"Neurology"},{"key":"2022042312263975000_fmac032-B12","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s12879-020-4891-5","article-title":"Quantitative assessment of lesion load and efficacy of 3 cycles of albendazole in disseminated cysticercosis: a prospective evaluation","volume":"20","author":"Pandey","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2022042312263975000_fmac032-B13","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1111\/epi.12749","article-title":"Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study","volume":"55","author":"Baulac","year":"2014","journal-title":"Epilepsia"},{"key":"2022042312263975000_fmac032-B14","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0920-1211(01)00271-6","article-title":"A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy","volume":"46","author":"Nieto-Barrera","year":"2001","journal-title":"Epilepsy Res"},{"key":"2022042312263975000_fmac032-B15","doi-asserted-by":"crossref","first-page":"106433","DOI":"10.1016\/j.eplepsyres.2020.106433","article-title":"Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy","volume":"167","author":"Hu","year":"2020","journal-title":"Epilepsy Res"},{"key":"2022042312263975000_fmac032-B16","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1212\/01.WNL.0000129481.12067.06","article-title":"Calcific neurocysticercosis and epileptogenesis","volume":"62","author":"Nash","year":"2004","journal-title":"Neurology"},{"key":"2022042312263975000_fmac032-B17","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1212\/WNL.44.9.1706","article-title":"Prognostic factors for seizure recurrence after withdrawal of antiepileptic drugs in patients with neurocysticercosis","volume":"44","author":"Del Brutto","year":"1994","journal-title":"Neurology"},{"key":"2022042312263975000_fmac032-B18","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0920-1211(01)00296-0","article-title":"A systematic review of the safety profile of levetiracetam: a new antiepileptic drug","volume":"47","author":"French","year":"2001","journal-title":"Epilepsy Res"},{"key":"2022042312263975000_fmac032-B19","first-page":"157","article-title":"Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas","volume":"54","author":"Kaushal","year":"2006","journal-title":"Neurol India"},{"key":"2022042312263975000_fmac032-B20","first-page":"375","article-title":"Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis","volume":"71","author":"Cotton","year":"2011","journal-title":"J Trauma"},{"key":"2022042312263975000_fmac032-B21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/adc.2009.167361","article-title":"Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction","volume":"95","author":"H\u00f6gler","year":"2010","journal-title":"Arch Dis Child"},{"key":"2022042312263975000_fmac032-B22","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/00007691-200206000-00003","article-title":"Pharmacokinetic interaction between albendazole sulfoxide enantiomers and antiepileptic drugs in patients with neurocysticercosis","volume":"24","author":"Lanchote","year":"2002","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Tropical Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/68\/3\/fmac032\/43426771\/fmac032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/68\/3\/fmac032\/43426771\/fmac032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,22]],"date-time":"2024-09-22T08:51:05Z","timestamp":1726995065000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tropej\/article\/doi\/10.1093\/tropej\/fmac032\/6572713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,4,5]]}},"URL":"https:\/\/doi.org\/10.1093\/tropej\/fmac032","relation":{},"ISSN":["0142-6338","1465-3664"],"issn-type":[{"value":"0142-6338","type":"print"},{"value":"1465-3664","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2022,4,5]]},"article-number":"fmac032"}}